Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
Top Page
Allogene Therapeutics
(NASDAQ:ALLO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▼(-16.32% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance (minimal revenue, persistent losses, and substantial cash burn) and limited valuation support with negative earnings. Offsetting factors are constructive earnings-call takeaways (extended runway into 2029 and encouraging early clinical/safety signals) and a neutral-to-mixed technical picture.
Positive Factors
Cash runway
A strengthened balance sheet with cash plus recent offering proceeds extending runway into Q1 2029 materially reduces near‑term financing risk. This gives management time and flexibility to complete ALPHA3 enrollment, reach the mid‑2027 interim EFS readout, and advance ALLO‑329 dose escalation without urgent capital constraints.
Negative Factors
No product revenue
The company remains pre‑commercial with essentially no recurring product revenue and persistent large losses. Without commercialization, Allogene must rely on external funding to sustain operations, limiting self‑funding capacity and placing long‑term strategic execution at the mercy of financing access and clinical success.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway
A strengthened balance sheet with cash plus recent offering proceeds extending runway into Q1 2029 materially reduces near‑term financing risk. This gives management time and flexibility to complete ALPHA3 enrollment, reach the mid‑2027 interim EFS readout, and advance ALLO‑329 dose escalation without urgent capital constraints.
Read all positive factors
Allogene Therapeutics (ALLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$669.60M
Dividend YieldN/A
Average Volume (3M)13.71M
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue GrowthN/A
EPS Growth37.45%
CountryUS
Employees226
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.77
Shares Outstanding345,154,570
10 Day Avg. Volume6,867,900
30 Day Avg. Volume13,713,527
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.86
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$8.71Price Target Upside264.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$13.85K
Allogene Therapeutics Business Overview & Revenue Model
Company Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic...
How the Company Makes Money
Allogene Therapeutics is a clinical-stage company and does not have recurring product sales from commercialized therapies. Its revenue has primarily been generated from collaboration and licensing arrangements, including payments related to partne...
Allogene Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.Positive Updates
ALPHA3 Interim MRD Efficacy Signal
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
Negative Updates
Preliminary Nature and Small Size of Interim Data
ALPHA3 interim results are based on a small 24-patient analysis and rely on the assumption that MRD clearance will translate to EFS benefit — EFS impact remains unconfirmed until planned interim/primary analyses.
Read all updates
Q1-2026 Updates
Positive
Negative
ALPHA3 Interim MRD Efficacy Signal
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
Read all positive updates
Company Guidance
Allogene reported a March 31 cash balance of $266.9M and approximately $200.4M of gross proceeds from an April offering, extending its cash runway into Q1 2029; Q1 spend included R&D of $32M (inc. $2.7M non‑cash stock comp), G&A of $14.1M (inc. $5.6M non‑cash), and a net loss of $42.6M or $0.18/share (inc. $8.3M non‑cash). Management modestly raised 2026 operating cash expense guidance from ~ $150M to ~ $165M and GAAP operating expense guidance from ~ $210M to ~ $225M (including an estimated ~$35M of non‑cash stock comp), excluding any M&A impact. Key clinical timing guidance: complete ALPHA3 enrollment by end‑2027 with an interim EFS analysis in mid‑2027 and primary EFS analysis in mid‑2028 (BLA filing to follow as appropriate); ALPHA3 is now enrolling at >60 sites with planned expansion to >80 globally. They also expect an ALLO‑329 update in Q4 2026 after initial dosing (9 patients to date: 3 at 20M cells + cyclophosphamide, 3 at 40M + cyclophosphamide, 3 at 20M without lymphodepletion); management noted the ALPHA3 interim futility (n=24) showed a 58.3% vs 16.7% MRD clearance (41.6‑point absolute difference) and median ctDNA −~98% at day 45 versus +>26% in observation, which they say supports execution within the provided financial runway.Allogene Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 22.00K | 95.00K | 156.00K | 114.09M |
| Gross Profit | -37.09M | -12.36M | 22.00K | 95.00K | -14.14M | 114.09M |
| EBITDA | -168.10M | -194.57M | -243.33M | -313.07M | -321.24M | -169.74M |
| Net Income | -173.76M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
Balance Sheet | ||||||
| Total Assets | 395.96M | 415.90M | 548.71M | 642.84M | 821.58M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 266.89M | 250.21M | 292.48M | 448.70M | 517.32M | 457.30M |
| Total Debt | 81.05M | 75.05M | 90.76M | 95.12M | 101.12M | 73.13M |
| Total Liabilities | 117.08M | 123.36M | 126.53M | 130.60M | 154.70M | 125.63M |
| Stockholders Equity | 278.88M | 292.54M | 422.18M | 512.23M | 666.88M | 925.20M |
Cash Flow | ||||||
| Free Cash Flow | -109.53M | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Operating Cash Flow | -109.23M | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Investing Cash Flow | 59.80M | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Financing Cash Flow | 37.29M | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
Allogene Therapeutics Technical Analysis
Negative
2.39
Price Trends
2.35
Negative
2.09
Negative
1.66
Positive
Market Momentum
-0.09
Positive
35.29
Neutral
7.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Negative. The current price of 2.39 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.35, and above the 200-day MA of 1.66, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 35.29 is Neutral, neither overbought nor oversold. The STOCH value of 7.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLO.
Allogene Therapeutics Risk Analysis
Allogene Therapeutics disclosed 78 risk factors in its most recent earnings report. Allogene Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allogene Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $306.06M | -3.71 | 41.40% | ― | ― | ― | |
52 Neutral | $669.60M | -3.44 | -56.45% | ― | ― | 37.45% | |
52 Neutral | $169.91M | -1.37 | -80.56% | ― | ― | 59.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $327.95M | -1.64 | -181.70% | ― | ― | 17.61% | |
46 Neutral | $224.29M | -4.18 | 85.78% | ― | 20.08% | 14.06% |
* Healthcare Sector Average
ALLO
Allogene Therapeutics
1.90
0.79
71.17%
ABEO
Abeona Therapeutics
5.32
-1.13
-17.52%
FHTX
Foghorn Therapeutics
4.00
-0.06
-1.48%
TNYA
Tenaya Therapeutics
0.81
0.37
82.81%
NMRA
Neumora Therapeutics, Inc.
1.72
0.97
129.33%
Allogene Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Allogene Highlights ALPHA3 Data and Extended Cash Runway
Positive
May 13, 2026
On May 12, 2026, Allogene terminated its exclusive license agreement with Overland Therapeutics covering four allogeneic CAR T targets in parts of Asia, relinquished a portion of its equity and governance rights, and now expects to hold about 3% o...
Business Operations and StrategyPrivate Placements and Financing
Allogene Therapeutics Prices Large Common Stock Offering
Neutral
Apr 15, 2026
On April 13 and 14, 2026, Allogene Therapeutics launched and priced an underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, targeting gross proceeds of about $175 million before fees and expenses. The deal, led by ...
Business Operations and StrategyPrivate Placements and Financing
Allogene Therapeutics Launches New Underwritten Common Stock Offering
Neutral
Apr 13, 2026
On April 13, 2026, Allogene Therapeutics announced it had commenced an underwritten public offering of its common stock, marking a new effort to raise capital through the equity markets to support its business activities. In conjunction with the n...
Business Operations and StrategyProduct-Related Announcements
Allogene Highlights Positive Interim ALPHA3 CAR T Data
Positive
Apr 13, 2026
On April 13, 2026, Allogene Therapeutics reported an interim futility analysis from its pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel as a first‑line consolidation therapy for high‑risk large B‑cell lymphoma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.